Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Enesi Pharma Limited.

    Client Virtual Booth

    ENESI PHARMA LIMITED

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Enesi Pharma Limited
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    120 A&B Olympic Avenue, Milton Park, Abingdon Oxfordshire, OX14 4SA
    Telephone
    Telephone
    +44 (0) 1235 577 120
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.enesipharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/enesipharma
    Twitter
    Twitter
    https://twitter.com/enesi_pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Enesi Pharma Enters Agreement with National Institutes of Health to Evaluate ImplaVax®-enabled Flu Vaccines

    Details:

    ImplaVax®-enabled vaccination products leverage Enesi’s innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats such as recombinant H7N9 pandemic influenza vaccine.


    Lead Product(s): Recombinant Influenza Vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Vaccine

    Partner/Sponsor/Collaborator: National Institutes of Health

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement October 19, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Enesi Pharma and Imperial College London Collaborate to Develop Thermostable RNA Vaccines for Covid-19

    Details:

    The collaboration will investigate the potential of combining Enesi's ImplaVax® technology for the creation of thermostable, solid dose vaccines with RNA vaccines based on Imperial's self-amplifying RNA technology and novel Polyplex DNA/RNA stabilisation technologies.


    Lead Product(s): RNA vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine

    Recipient: Imperial College London

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration December 18, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Enesi Pharma's ImplaVax®-Enabled Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Need...

    Details:

    Study investigating potential of solid-dose vaccine for porcine reproductive and respiratory syndrome virus (PRRSV) conducted in collaboration with The Pirbright Institute.


    Lead Product(s): PRRSV vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Vaccine

    Partner/Sponsor/Collaborator: The Pirbright Institute

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 29, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Enesi Pharma to Develop Thermostable Solid Dose DNA Vaccine Targeting Zika Virus Under New Partnership with the University of Adelaide

    Details:

    This project aims to employ Enesi’s ImplaVax® formulation expertise and platform to create a protective Zika virus DNA vaccine in a solid dose implant format for transcutaneous delivery via a needle-free device.


    Lead Product(s): DNA vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Vaccine

    Recipient: University of Adelaide

    Deal Size: $0.9 million Upfront Cash: Undisclosed

    Deal Type: Collaboration September 03, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search